Skip to main content

Peptide Profile

CJC-1295 (without DAC)

CJC 1295 · CJC 1295 XDAC · CJC NO DAC · CJC-1295 · CJC-1295 no DAC · CJC-1295 no-DAC · CJC-1295 without DAC · CJC-1295 XDAC · Mod GRF 1-29 · Modified GRF 1-29 · Tetrasubstituted GRF 1-29

CJC-1295 without DAC — commonly called Mod GRF 1-29 — is a synthetic, truncated (1-29) growth hormone-releasing hormone (GHRH) analog. Unlike the DAC variant, it does not carry the albumin-binding Drug Affinity Complex, so its…

GH / IGF AxisResearch Only
Used forperformancelongevityfat loss
Half-life
~30 minutes
Routes
subcutaneous
Find providers View evidence

Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.

Educational research tools — not medical advice.

Overview

What CJC-1295 (without DAC) is

About CJC-1295 (without DAC)

CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.

CJC-1295 without DAC — commonly called Mod GRF 1-29 — is a synthetic, truncated (1-29) growth hormone-releasing hormone (GHRH) analog. Unlike the DAC variant, it does not carry the albumin-binding Drug Affinity Complex, so its effective half-life is measured in minutes rather than days. It binds pituitary GHRH receptors and, in research contexts, is associated with short, pulsatile stimulation of growth hormone secretion that more closely mimics the body's natural GH rhythm. The distinction from the DAC form is central and is why PeptideBase catalogs them as separate records. The DAC form (CJC-1295 DAC) binds circulating albumin and produces multi-day, sustained GHRH-receptor signaling; the non-DAC form here acts for only about half an hour, producing brief discrete pulses. Researchers describe them as different pharmacokinetic tools rather than interchangeable versions of one compound. The indexed human evidence base for the non-DAC form is very limited and largely mechanistic. CJC-1295 without DAC has no FDA approval and no approved therapeutic indication in any jurisdiction — it is available only as a research compound, and no Phase 2 or Phase 3 efficacy data exists for any specific application. Content here is educational and for research context only; it is not medical, dosing, or treatment guidance.

Women's Health

No controlled human data exist for CJC-1295 in any women's-health context; the only female-specific usage information is qualitative forum/netnography research, not clinical evidence. The original human pharmacokinetic trial was conducted in non-menopausal healthy adults and did not evaluate menopausal or reproductive endpoints. CJC-1295 is an unapproved research compound with no human pregnancy/lactation safety data.

CJC-1295 (without DAC) Benefits & Research Areas

GH and IGF-1 elevationsustained GHRH receptor agonismbody composition supportrecovery enhancement

Research Signals

Commonly researched in the context of

Calorie DeficitHigh Training Load

Population research notes

30s40s50+

These signals reflect research interest areas, not treatment indications.

Pharmacokinetics

CJC-1295 (without DAC) half-life calculator

Compound & timing

Half-lifefrom PeptideBase data
Source: "~30 minutes" · CJC-1295 (without DAC) (PeptideBase)
to show amount remaining
30 min
0%25%50%75%100%0316294125156time since dose (min)
Plasma decay curve for CJC-1295 (without DAC): 50% remaining at 30 min after the dose.
plasma level
50%remaining in plasmaat 30 min after the dose
Half-life
30 min
~97% cleared after
2.5 h

Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.

The Research

What the evidence says about CJC-1295 (without DAC)

Research Evidence

based on 3 studies · 2 RCTs · most recent 2026

Regulatory Status

Availability Status
Research Only
FDA Status
Source
View FDA source →

GHRH analog — the truncated 1-29 form (Mod GRF 1-29), WITHOUT the Drug Affinity Complex (DAC). No FDA approval; not on the FDA 503A bulks list. WADA prohibited (S2) as a growth-hormone-releasing factor. Sold as a research chemical only.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Research Sources

3 sources cited · 2 strong · 1 weak

2 RCTs · 1 Review

  • Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women

    Journal of Clinical Endocrinology and Metabolism · 1997

    Research in a 5-month randomized placebo-controlled trial found that nightly subcutaneous administration of a GHRH(1-29) analog significantly increased 12-hour integrated GH levels, serum IGF-I, and IGFBP-3, with increases in lean body mass in men, improved skin thickness in both sexes, and enhanced insulin sensitivity and well-being in men.

    RCTn=19StrongPMID 9141536

  • Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women

    Journal of Clinical Endocrinology and Metabolism · 1997

    Research in a randomized controlled trial found that 4-month nightly GHRH analog administration significantly increased GH secretion and IGF-I levels while also enhancing immune cell activation, including B cell numbers, T cell receptor expression, and interleukin-2 responsiveness in elderly men and women, without sex differences in immune response.

    RCTn=19StrongPMID 9360512

  • Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

    JBJS Rev · 2026

    # Summary of CJC-1295 Research Finding Research found that CJC-1295, classified as a growth hormone axis secretagogue, remains investigational with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions in the context of sports medicine applications. This study demonstrated that injectable peptides in this functional class lack the reproducible clinical evidence supporting other peptide categories and are not currently established as clinically adopted treatments for musculoskeletal recovery or tissue repair.

    ReviewTheoreticalPMID 42160466

CJC-1295 (without DAC) Side Effects & Safety Considerations

No FDA-approved label for this compound. Cautions below are extrapolated from its mechanism/drug class — investigational; educational only.

Warnings & cautions

Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Common monitoring markers in research protocols

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

IGF-1Fasting glucoseHbA1cInsulin

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Known Interactions

2 noted

Pharmaceutical interactions are noted for research awareness. Always consult your prescriber before combining CJC-1295 (without DAC) with any medication.

Synergistic1
Ipamorelin
Documented

Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.

Teichman SL et al. (2006) Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab; Raun K et al. (1998) Ipamorelin. Eur J Endocrinol

Use With Caution1
GLP-1 agonistsPharmaceutical
Emerging

Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.

Drucker DJ (2018) Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab; Veldhuis JD et al. (2008) GH secretagogue interactions. J Clin Endocrinol Metab

These interactions reflect published research and are provided for educational purposes only. This is not medical advice. Consult a qualified healthcare professional before combining any compounds or medications.

Compare

VS

CJC-1295 (without DAC)

Third-party testing data

6 verified COAs

Median tested purity

99.7%

Median tested purity of 99.7% across 6 verified third-party lab COAs (interquartile range 99.6%–99.8%), as reported by the independent testing labs below. PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product.

Independent labs
Freedom Diagnostics, Janoshik Analytical, TrustPointe Analytics LLC
Most recent test
June 2026

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Certificates of Analysis

Cross-vendor verified27 COAs on record for CJC-1295 (without DAC)

PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Confirmed by lab results were matched against the issuing laboratory's own records — either the lab served the document, or its own hosted copy matches ours byte for byte. For every other result the badge states what is known about the lab: that it can be checked and no result is recorded yet, that it can't be checked, or that we have not reviewed it.

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Community Experience

What people report about CJC-1295 (without DAC)

n=42high confidence

Self-reported, anecdotal experiences aggregated from public Reddit discussions — community sentiment, not clinical evidence or medical advice.

Attribution note: many of these reports describe stacking CJC-1295 (without DAC) with other compounds, so outcomes may not be attributable to it alone.

Outcome distribution

55%improved
Improved
23 · 55%
Mixed
9 · 21%
No clear effect
7 · 17%
Worse
3 · 7%

Outcomes by goal · improved % · reports

Fat loss57% improved · 14 reports
Sleep quality88% improved · 8 reports
Muscle & strength43% improved · 7 reports
Recovery & performance25% improved · 4 reports

Side effects people mention

Counts are mentions across reports, not incidence rates.

Water retention7
Injection site reaction5
Elevated heart rate3
Vivid dreams3
Numbness tingling2
Decreased appetite1
Fatigue1
Nausea1

Most reported

  • Sleep quality improved markedly, often described as deeper and more restorative than before14×thread 1thread 2thread 3
  • Body composition shifted positively, with users noting fat loss and improved muscle definition12×thread 1thread 2thread 3
  • Early water retention and bloating were common initial experiences that tended to subside6×thread 1thread 2thread 3
  • Allergic or immune reactions including itching, hives, and elevated heart rate were reported by some users5×thread 1thread 2thread 3
  • Stacking with other compounds sometimes amplified side effects such as night sweats, tingling, and fatigue5×thread 1thread 2thread 3

What they wish they'd known

  • Early water retention is temporary and tends to normalize on its own within the first week or two5×thread 1thread 2thread 3
  • Combining this peptide with exogenous growth hormone often produces overlapping and disruptive side effects3×thread 1thread 2thread 3
  • Results vary widely and some users experience little to no noticeable benefit despite consistent use4×thread 1thread 2thread 3

Based on 42 community reports · Updated

Frequently Asked Questions — CJC-1295 (without DAC)

CJC-1295 without DAC — commonly called Mod GRF 1-29 — is a synthetic, truncated (1-29) growth hormone-releasing hormone (GHRH) analog. Unlike the DAC variant, it does not carry the albumin-binding Drug Affinity Complex, so its effective half-life is measured in minutes rather than days.

GH and IGF-1 elevation, sustained GHRH receptor agonism, body composition support, recovery enhancement, GH axis restoration.

Research on CJC-1295 (without DAC) primarily documents effects related to GH and IGF-1 elevation and sustained GHRH receptor agonism and body composition support and recovery enhancement and GH axis restoration. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for CJC-1295 (without DAC) include Active malignancy — caution (GH/IGF-1 is mitogenic), Pregnancy — caution, Known hypersensitivity. 1 additional consideration are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.

For CJC-1295 (without DAC), its FDA status is Nomination Withdrawn, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

372 providers in the directory currently offer CJC-1295 (without DAC).

Across 42 research vendors tracked on PeptideBase, CJC-1295 (without DAC) has a median price of about $8.20 per mg, typically ranging $7.07–$11.29 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

Research in a 5-month randomized placebo-controlled trial found that nightly subcutaneous administration of a GHRH(1-29) analog significantly increased 12-hour integrated GH levels, serum IGF-I, and IGFBP-3, with increases in lean body mass in men, improved skin thickness in both sexes, and enhanced insulin sensitivity and well-being in men.

CJC-1295 (without DAC) is featured in the following research stacks on PeptideBase: CJC-1295 + Ipamorelin + BPC-157: Recovery & GH, CJC-1295 + Ipamorelin + GHRP-6: GH Secretagogue Max, CJC-1295 + Ipamorelin: GH Optimization, Hexarelin + Mod GRF 1-29: Anabolic GH Amplification.

Access

How to get CJC-1295 (without DAC)

Market Pricing

42 vendors
$7.07/mgBudget
$8.20/mgMedian
$11.29/mgPremium
$7.07
$8.20
$11.29

Price per mg varies by quantity, vendor type, and formulation. Research use only.

Data verified August 2026 · CJC-1295 (without DAC) price intelligence

Compare 42 vendors →
Compare all 42 vendors →

Where to buy CJC-1295 (without DAC)

372 providers
●287 Clinics●18 Telehealth●8 Pharmacies●57 Online Vendors●2 Physicians449 in stock5 on request

Compounding Pharmacies (503A)

1 provider
View all 372 providers →

Research stacks

Browse all →

Commonly stacked with

BPC-157GHRP-6HexarelinIpamorelin

Questions to ask your provider

Stay updated on CJC-1295 (without DAC) providers

New providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Last updated

Keep exploring

Tools & Guides

Reconstitution Calculator

Convert vial size + BAC water volume into draw volume.

How to Reconstitute Peptides

Step-by-step guide: BAC water, vial prep, and storage after mixing.

Peptide Dosage Guide

Key factors that determine dosing in clinical practice.

Peptide Storage Guide

How to store lyophilized and reconstituted peptides.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 (without DAC) — Per-mg Price Benchmark. Retrieved September 11, 2026, from https://peptidebase.io/peptides/cjc-1295
https://peptidebase.io/peptides/cjc-1295MethodologyLicenseDownload JSONDownload CSV

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.